Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study

Basit Öğe Kaydı
dc.contributor.authorYavas, C.
dc.contributor.authorDogan, U.
dc.contributor.authorYavas, G.
dc.contributor.authorAraz, M.
dc.contributor.authorAta, O. Yavas
dc.date.accessioned2020-03-26T18:23:42Z
dc.date.available2020-03-26T18:23:42Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPalonosetron is a novel 5-hydroxytryptamine(3) (5 HT3) receptor antagonist, which has been shown to be superior to first generation 5 HT3 receptor antagonists regarding the prevention of acute, delayed and overall chemotherapy-induced nausea and vomiting. First generation 5 HT3 receptor antagonists may induce electrocardiographic changes of heart rate and repolarization. The acute cardiac effect of palonosteron is unknown. The purpose of this study is to determine acute effects of palonosetron on electrocardiographic (ECG) parameters in cancer patients. The study had a prospective design. Seventy-six cancer patients with normal cardiac function who received palonosetron for prevention of chemotherapy-induced nausea and vomiting were enrolled. Standard 12-lead ECG recordings were performed at baseline and 30 min after palonosetron administration. P wave durations and corrected QT intervals were measured; P wave dispersion (Pd) and QTc dispersion were calculated. Median heart rate did not differ among 76 patients enrolled before and after palonosetron administration (p: 0.6). Systolic and diastolic blood pressures were not significantly different before and after palonosteron (p values 0.9 and 0.3, respectively). Although median QT min value was higher after palonosetron administration than before palonosetron administration, the difference was not statistically significant (p: 0.6). Palonosetron seems to have no acute arrhythmogenic potential.en_US
dc.identifier.doi10.1007/s00520-011-1348-9en_US
dc.identifier.endpage2347en_US
dc.identifier.issn0941-4355en_US
dc.identifier.issn1433-7339en_US
dc.identifier.issue10en_US
dc.identifier.pmid22170340en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2343en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00520-011-1348-9
dc.identifier.urihttps://hdl.handle.net/20.500.12395/27709
dc.identifier.volume20en_US
dc.identifier.wosWOS:000308193500012en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofSUPPORTIVE CARE IN CANCERen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectCardiac effecten_US
dc.subjectEectrocardiographyen_US
dc.subject5HT(3) receptor antagonist, Palonosetronen_US
dc.titleAcute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu